Synmosa Biopharma (4114) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$185.72 Million ≈ $5.85 Million USD) by net assets (NT$10.10 Billion ≈ $318.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Synmosa Biopharma defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Synmosa Biopharma - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solowin Holdings Ordinary Share
NASDAQ:SWIN
|
-0.050x |
|
ION Exchange (India) Limited
NSE:IONEXCHANG
|
-0.006x |
|
B&S Group SA
AS:BSGR
|
0.036x |
|
Skjern Bank A/S
CO:SKJE
|
0.007x |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
0.029x |
|
HANGZHOU TIGERMED CO. H 1
F:5HZ1
|
N/A |
|
Jiangsu Hengxing New Material
SHG:603276
|
0.012x |
|
Zhejiang Extek Technology Co. Ltd. A
SHE:301399
|
N/A |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2025)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Synmosa Biopharma (4114) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
NT$411.57 Million ≈ $12.97 Million |
0.041x | -56.15% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
NT$780.62 Million ≈ $24.59 Million |
0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
NT$511.93 Million ≈ $16.13 Million |
0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
NT$630.25 Million ≈ $19.86 Million |
0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
NT$444.29 Million ≈ $14.00 Million |
0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
NT$254.40 Million ≈ $8.02 Million |
0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
NT$-44.88 Million ≈ $-1.41 Million |
-0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
NT$16.00 Million ≈ $503.96K |
0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
NT$-5.19 Million ≈ $-163.64K |
-0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
NT$236.48 Million ≈ $7.45 Million |
0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
NT$23.60 Million ≈ $743.59K |
0.008x | -- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more